David Sinclair Longevity Protocols: What Clinicians Should Tell Patients

Who Is David Sinclair and Why Do Patients Ask About Him?

David Sinclair is a Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book Lifespan: Why We Age and Why We Don't Have To reached the New York Times bestseller list, and his appearances on podcasts with audiences numbering in the tens of millions have made him one of the most cited figures in lay longevity discourse.

Sinclair's core thesis, described in his published work and public statements, is that aging is an "information loss" problem at the epigenetic level and that sirtuins, a family of NAD-dependent deacetylases, are central regulators of that process. He has described his personal supplement and drug regimen in detail across multiple podcast appearances, including a widely circulated 2022 episode of the Lex Fridman Podcast and posts on X (formerly Twitter).

Why This Matters Clinically

Patients arrive at appointments having already read the book or listened to the podcast. A 2023 JAMA Internal Medicine survey found that 57% of adults who follow health influencers report purchasing supplements based on that content. Dismissing Sinclair's protocol without engaging the underlying science erodes trust. Engaging it without knowing the evidence gaps creates liability.

What Sinclair Actually Claims

Sinclair has been careful to label his regimen as a personal experiment, not a clinical recommendation. In a 2023 interview with Andrew Huberman, he stated: "I'm not recommending anyone take what I take. I'm a scientist doing an experiment on myself." Clinicians can use that framing as a starting point for patient conversations.

The NMN and NAD+ Precursor Question

NAD+ (nicotinamide adenine dinucleotide) declines with age in multiple tissues. Sinclair reports taking 1 gram of NMN (nicotinamide mononucleotide) each morning, citing its role as an NAD+ precursor and its ability to activate sirtuins.

What the Rodent Data Show

In mouse models, NMN supplementation has restored NAD+ levels, improved mitochondrial function, and extended median lifespan in some strains. A 2016 Cell Metabolism paper by Mills et al. (N=mice) showed that 12 months of NMN supplementation suppressed age-associated weight gain, improved energy metabolism, and enhanced physical activity without obvious toxicity [1]. These findings are real and worth knowing. They are also mouse data.

Human Trial Evidence

The first double-blind, placebo-controlled human RCT of NMN, published in Science in 2021 by Yoshino et al. (N=25 postmenopausal women with prediabetes), showed that 250 mg/day of NMN for 10 weeks raised skeletal muscle NAD+ metabolite levels and improved insulin signaling in muscle but did not change insulin sensitivity on a whole-body glucose clamp [2]. The trial was too small and too short to assess aging or mortality endpoints.

A 2023 randomized trial by Yi et al. (N=80 healthy adults aged 40-65) showed that 300 mg/day of NMN raised blood NAD+ levels at 60 days but found no statistically significant change in biological age markers, VO2 max, or inflammatory cytokines [3].

The Clinician Bottom Line on NMN

NMN appears safe at doses up to 1,200 mg/day based on a 2020 phase 1 safety study by Irie et al. [4]. Raising blood NAD+ is biologically plausible and likely achievable. Whether that translates to slower aging in humans remains unproven. Patients can be told: the mechanism is credible, the human longevity evidence does not yet exist, and cost (typically $60-$120/month) should factor into their decision.

Metformin as a Longevity Drug

Metformin is the most evidence-rich compound on Sinclair's list, and also the one with the most clinically relevant trade-off data.

The Observational Case

A landmark 2014 observational study by Bannister et al. In Diabetologia (N=78,241 type 2 diabetes patients) found that metformin users had lower all-cause mortality than matched non-diabetic controls, suggesting a benefit beyond glucose control [5]. This finding catalyzed the TAME (Targeting Aging with Metformin) trial, an NIDDK-funded phase 3 RCT enrolling 3,000 adults aged 65-79 without diabetes, expected to report primary outcomes around 2026.

The Exercise Adaptation Problem

A critical counter-data point: the MILES (Metformin In Longevity Study) trial, published in Aging Cell by Walton et al. (N=53 sedentary older adults), found that metformin blunted the improvements in insulin sensitivity and mitochondrial respiration that normally follow 12 weeks of aerobic exercise training [6]. For patients who exercise regularly (which Sinclair also recommends), this is a genuine tension clinicians should surface.

Prescribing Considerations

Metformin requires a prescription in the United States. Off-label prescribing for longevity is legal but places the prescribing burden on the clinician. Contraindications include eGFR <30 mL/min/1.73m2, active hepatic disease, and contrast procedures. The 2022 American Diabetes Association Standards of Care note that metformin remains "the preferred initial agent" for type 2 diabetes management but make no recommendation for longevity use in non-diabetic individuals [7].

Resveratrol: Sinclair's Founding Molecule

Resveratrol is the compound that launched much of Sinclair's public career. His 2003 Nature paper with Howitz et al. Showed that resveratrol activated Sir2 (the yeast sirtuin homolog) and extended yeast lifespan by up to 70% [8]. Sinclair reports taking 1 gram of resveratrol daily, dissolved in yogurt or olive oil to improve bioavailability.

Where the Human Data Fell Apart

GSK licensed resveratrol-based compounds and ran multiple clinical trials. SRT501, a formulated resveratrol product, showed signs of renal toxicity in a myeloma trial and was discontinued. A 2012 JAMA Internal Medicine study by Semba et al. (N=783 community-dwelling older adults, Invecchiare in Chianti cohort) found that urinary resveratrol metabolites were not associated with inflammatory markers, cardiovascular disease, cancer, or mortality over 9 years [9].

The Bioavailability Ceiling

Oral resveratrol is rapidly metabolized in the gut and liver. Plasma concentrations after a 1 g oral dose typically peak below 40 ng/mL and fall within two hours. The concentrations required to activate sirtuins in cell-free assays are orders of magnitude higher. Some researchers have argued the in vitro sirtuin activation was a fluorescence artifact, a point that generated significant scientific controversy in 2009-2010.

Clinical Counseling Point

Resveratrol is generally safe at doses up to 1 g/day. The primary drug interaction concern is CYP2C9 inhibition, which can raise warfarin and certain NSAID levels. For patients on anticoagulants, this is a concrete reason to advise against high-dose resveratrol without INR monitoring.

Rapamycin: The Most Potent and Least Studied Option

Rapamycin (sirolimus), an mTOR inhibitor approved by the FDA for organ transplant rejection and certain cancers, has the strongest cross-species lifespan extension data of any compound discussed here.

The ITP Data

The Interventions Testing Program (ITP), an NIA-funded multi-site mouse study, found that rapamycin extended median lifespan by 9-14% in both male and female mice even when started at 20 months of age (equivalent to roughly age 60 in humans) [10]. This effect has been replicated across multiple ITP cohorts, making it one of the most reproducible longevity findings in mammals.

Human Safety Profile at Longevity Doses

Therapeutic immunosuppressive doses of rapamycin (2-5 mg/day continuous) cause significant adverse effects including impaired wound healing, hyperlipidemia, mouth ulcers, and increased infection risk. The longevity dosing that Sinclair and others in the field discuss is intermittent, typically 5-6 mg once weekly, a regimen used in the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), which enrolled healthy adults aged 50-85 and reported in 2023 that the protocol appeared safe over 48 weeks with no increase in serious adverse events vs. Placebo [11].

No Completed Efficacy RCT

PEARL was a safety and feasibility trial. No completed phase 3 RCT has demonstrated that rapamycin extends lifespan or healthspan in healthy humans. Prescribing rapamycin off-label for longevity remains at the outer edge of evidence-based medicine. Clinicians who do so should document the patient's understanding of this explicitly.

The Sirtuin and Epigenetic Clock Framework

Sinclair's theoretical framework holds that sirtuins, particularly SIRT1, act as epigenetic "guardians" that lose focus as NAD+ levels decline with age, causing gene expression errors that mimic aging. This is described in detail in his Cell review paper from 2013 [12].

Biological Age Testing

Sinclair regularly discusses biological age scores derived from DNA methylation clocks (Horvath clock, GrimAge). These tools are commercially available and patients may arrive having already purchased a test from companies like TruMe or Elysium Health. Clinicians should know that methylation clocks predict mortality risk with moderate accuracy in population data but have not been validated as surrogate endpoints in interventional trials. A change in clock age score does not yet meet FDA surrogate endpoint criteria for any compound.

What the Epigenetic Reprogramming Work Means

Sinclair's lab published a 2020 Nature paper by Lu et al. Showing that partial reprogramming with Yamanaka factors (OSK) restored vision in aged mice with glaucoma [13]. This is genuinely exciting basic science. It is also years from clinical application. Patients excited about this work can be directed to clinicaltrials.gov to understand the gap between mouse model and human therapy.

Sinclair's Lifestyle Practices: The Underreported Evidence Layer

Beyond supplements and drugs, Sinclair reports intermittent fasting (skipping breakfast and often lunch), a mostly plant-based diet, regular aerobic and resistance exercise, cold exposure, and sleep optimization. These practices have stronger human RCT evidence than any compound on his list.

Caloric restriction and time-restricted eating reduce insulin resistance, inflammatory markers, and cardiovascular risk factors in multiple trials. The CALERIE-2 trial (N=218) showed that 25% caloric restriction over 2 years reduced cardiometabolic risk factors significantly in non-obese adults [14]. Exercise reduces all-cause mortality with an effect size larger than any supplement yet tested in humans.

Clinicians can use the following practical triage framework when a patient presents Sinclair's protocol:

Tier 1 (Evidence supports discussion and possible use): Metformin in pre-diabetic patients (standard of care consideration regardless of longevity framing); time-restricted eating; resistance plus aerobic exercise; sleep quality optimization.

Tier 2 (Plausible mechanism, safety data adequate, efficacy unproven): NMN at doses up to 500 mg/day; resveratrol at doses up to 500 mg/day with CYP2C9 interaction screening.

Tier 3 (Requires explicit informed consent and close monitoring if used): Off-label metformin in non-diabetic adults pending TAME results; intermittent rapamycin (document immunosuppression risk, infection risk, and absence of efficacy data).

Drug Interactions and Safety Screening Checklist

Clinicians should screen for the following before any patient self-starts these compounds.

Metformin Interactions

• Contrast dye: hold 48 hours before and after iodinated contrast in patients with eGFR <60.
• Alcohol: increases lactic acidosis risk.
• Cimetidine and dolutegravir: raise metformin plasma levels via OCT2 inhibition.

Resveratrol Interactions

• Warfarin: CYP2C9 inhibition may raise INR unpredictably.
• Tamoxifen: resveratrol has estrogenic activity at low doses; avoid in ER-positive breast cancer patients.
• Statins: CYP3A4 inhibition may modestly raise simvastatin and lovastatin AUC.

Rapamycin Interactions

• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): can multiply rapamycin blood levels.
• Live vaccines: contraindicated during rapamycin use.
• Nephrotoxic agents: additive risk even at low doses.

How to Have the Conversation

Patients who arrive with Sinclair's protocol are engaged, motivated, and often have done more reading than the average patient. A dismissive response will lose them. An uncritical endorsement creates risk.

A structured approach: acknowledge the quality of the science, separate mechanistic evidence from clinical evidence, identify which elements have human RCT support, and offer to monitor biomarkers if the patient proceeds. Ordering a baseline metabolic panel, lipid panel, and HbA1c before any of these agents is reasonable and creates a documented safety baseline.

The TAME trial primary outcome data, expected around 2026, will likely change the metformin conversation significantly. Patients can be told to revisit that decision point when those results publish in a peer-reviewed journal.

The American Federation for Aging Research's 2022 position statement notes: "There is currently insufficient evidence to recommend any pharmacological intervention for the primary prevention of aging in healthy individuals outside of a clinical trial." [15] That sentence, cited accurately, is a clinically defensible anchor for any conversation about Sinclair's protocol.